Search

AF solution

Chevron
Midbrain Organoid_main
Normal Organoid

Midbrain Organoid

Midbrain Organoid_main

  • Midbrain organoids closely resemble the human midbrain in structure and cell types.
▶ Resemble human midbrain in structure, cell types for accurate studies.
  • Midbrain organoids provide reliable data for testing the efficacy and toxicity of new drugs.
▶ Provide reliable data for testing drug efficacy, toxicity effectively.
  • Midbrain organoids enable the study of early human brain development processes.
▶ Study early human brain development processes facilitated by midbrain organoids.

Organism
Product Type
Organoid
Tissue
iPSC, ASC
Disease

Applications

Parkinson's disease

Inflammatory Bowel Disease (IBD) refers to a chronic condition characterized by inflammation within the gastrointestinal tract, causing inflammation of the intestinal walls.

Infectious Disease

As a virus-infected model, the
utilization of tonsil, adenoid, and lung organoids allows for the evaluation of antiviral drug efficacy and facilitates virus research.

Table of Contents

Generation process of mature human midbrain organoid

Our hPSC-derived human midbrain organoids can be cultured long-term using our proprietary differentiation technology and contain more mature and larger numbers of dopamine neurons.

Cellular and structural similarity

Our midbrain organoids have the genes and structural characteristics expressed in the human midbrain and are composed of a large number of dopamine neurons as well as various cells. When cultured for a long period of time, melanin in the substantia nigra that appears specifically in the midbrain can be observed.

Functional similarity

In our brain organoids, electrical signals from nerve cells, characteristic of the human brain, were detected.
Through this, it was confirmed that it is a functionally mature organoid, and through long-term culture, the brain waves that appear in premature babies can also be confirmed.

Parkinson disease modeling generation method

We can generate organoid models of neurodegenerative diseases through two methods.
The first method is to differentiate induced pluripotent stem cells into brain organoids and create a disease model by producing GBM cells and assembloids.
The second method is to destroy or overexpress the gene to be identified in normal induced pluripotent stem cells, differentiate them into organoids, and then create a disease model.

Result

We compared normal organoids to organoids from a Parkinson’s disease model.
Abnormal mitochondria were observed in the Parkinson’s disease model, and it was confirmed that there were fewer dopamine neurons in this organoid compared to normal organoids.

When the treatment candidate drug was treated with Parkinson’s disease organoids, it was confirmed that death of dopamine neurons was suppressed and abnormal mitochondrial function was restored.
In addition, ROS was confirmed to be reduced, so the organoid could be used to screen candidate drugs for Parkinson’s disease.

MitoSOX (ROS indicator)
JC-1 (Mitochondrial membrane potential